Deck Therapeutics
CEO: Soren Weis Dahl
DeckTherapeutics is pioneering the new field of “acute omega-3 fatty acid therapeutics”. Emulsions of our proprietary semi-synthetic omega-3 compounds are administered intravenously and exert immediate effect on multiple molecular pathways critical for controlling cellular apoptosis and necrosis.